Plasma Galectin-3 and urine proteomics predict FEV(1) improvement in omalizumab-treated patients with severe allergic asthma: Results from the PROXIMA sub-study()

BACKGROUND: Patients with severe allergic asthma (SAA) when treated with omalizumab may exhibit different extent of response. Identifying biomarkers that can predict the extent of treatment effectiveness in patients can be useful in personalizing omalizumab treatment. METHODS: Patients from the long...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:World Allergy Organ J
Main Authors: Riccio, Anna Maria, Mauri, Pierluigi, De Ferrari, Laura, Rossi, Rossana, Di Silvestre, Dario, Bartezaghi, Marta, Saccheri, Fabiana, Canonica, Giorgio Walter
Formato: Artigo
Idioma:Inglês
Publicado em: World Allergy Organization 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6992845/
https://ncbi.nlm.nih.gov/pubmed/32015785
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.waojou.2019.100095
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados